Treatment of interstitial lung diseases associated with connective tissue diseases

Expert Review of Clinical Pharmacology

Volumn 5, Issue 2, 2012, Pages 219-227

  Kobayashi, Akiko ^a,b   Okamoto, Hiroshi ^a  

^a Minami Otsuka Clinic   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

connective tissue diseases; interstitial lung diseases; rheumatoid arthritis; systemic sclerosis; treatment

Indexed keywords

AZATHIOPRINE; BOSENTAN; CARBON MONOXIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMATINIB; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NINTEDANIB; PENICILLAMINE; PIRFENIDONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS;

ADD ON THERAPY; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; COMBINATION OF PULMONARY FIBROSIS AND EMPHYSEMA; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DIFFERENTIAL DIAGNOSIS; DIFFUSING LUNG CARBON MONOXIDE CAPACITY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; FACE EDEMA; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LEG EDEMA; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG TRANSPLANTATION; LUNG VOLUME; MIXED CONNECTIVE TISSUE DISEASE; NAUSEA AND VOMITING; NONSPECIFIC INTERSTITIAL PNEUMONIA; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POLYMYOSITIS; PROTEINURIA; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; TOTAL LUNG CAPACITY; UNSPECIFIED SIDE EFFECT; USUAL INTERSTITIAL PNEUMONIA;

CONNECTIVE TISSUE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL;

EID: 84858411632     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.9     Document Type: Review

References (71)

1. Nakajima A, Inoue E, Tanaka E et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand. J. Rheumatol. 39, 360-367 (2010).
2. Maradit-Kremers H, Nicola PJ, Crowson CS et al. Cardiovascular death in rheumatoid arthritis: A population-based study. Arthritis Rheum. 52, 722-732 (2005).
3. Remy-Jardin M, Remy J, Cortet B, Mauri F et al. Lung changes in rheumatoid arthritis: CT findings. Radiology 193, 375-382 (1994).
4. Walker UA, Tyndall A, Czirják L et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials and Research Group database. Ann. Rheum. Dis. 66, 754-763 (2007).
5. Fathi M, Vikgren J, Boijsen M et al. Interstitial lung disease in polymyositis and DM: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 59, 677-685 (2008).
6. Marie I, Hachulla E, Chérin P et al. Interstitial lung disease in polymyositis and DM. Arthritis Rheum. 47, 614-622 (2002).
7. Papathanasiou MP, Constantopoulos SH, Tsampoulas C et al. Reappraisal of respiratory abnormalities in primary and secondary Sjögren's syndrome. A controlled study. Chest 90, 370-374 (1986).
8. Strimlan CV, Rosenow EC 3rd, Divertie MB et al. Pulmonary manifestations of Sjögren's syndrome. Chest 70, 354-361 (1976).
9. Wiedemann HP, Matthay RA. Pulmonary manifestations of systemic lupus erythematosus. J. Thorac. Imaging 7, 1-18 (1992).
10. Weinrib L, Sharma OP, Quismorio FP Jr. A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin. Arthritis Rheum. 20, 48-56 (1990).
11. Bodolay E, Szekanecz Z, Dévényi K et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford) 44, 656-661 (2005).
12. Lee HK, Kim DS, Yoo B et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 127, 2019-2027 (2005).
13. Highland KB, Silver RM. New developments in scleroderma interstitial lung disease. Curr. Opin. Rheumatol. 17, 737-745 (2005).
14. Parambil JG, Myers JL, Lindell RM et al. Interstitial lung disease in primary Sjögren syndrome. Chest 130, 1489-1495 (2006).
15. Douglas WW, Tazelaar HD, Hartman TE et al. Polymyositis-DM-associated interstitial lung disease. Am. J. Respir. Crit. Care Med. 164, 1182-1185 (2001).
16. Kanat F, Levendoglu F, Teke T. Radiological and functional assessment of pulmonary involvement in the rheumatoid arthritis patients. Rheumatol. Int. 27, 459-466 (2007).
17. Barrera P, Laan RF, van Riel PL et al. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann. Rheum. Dis. 53, 434-439 (1994).
18. Shidara K, Hoshi D, Inoue E et al. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod. Rheumatol. 20, 280-286 (2010).
19. Tokuda H, Sakai F, Yamada H et al. Clinical and radiological features of pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and pneumocystis pneumonia in acquired immunodeficiency syndrome: A multicenter study. Intern. Med. 47, 915-923 (2008).
20. Olsen NJ, Park JH, King LE Jr. Amyopathic DM. Curr. Rheumatol. Rep. 3, 346-351 (2001).
21. Koyama M, Johkoh T, Honda O et al. Pulmonary involvement in primary Sjögren's syndrome: spectrum of pulmonary abnormalities and computed tomography findings in 60 patients. J. Thorac. Imaging 16, 290-296 (2001).
22. Cottin V, Nunes H, Brillet PY et al.; Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: A distinct underrecognised entity. Eur. Respir. J. 26, 586-593 (2005).
23. Cottin V, Nunes H, Mouthon L et al.; Groupe d'Etudes et de Recherche sur les Maladies 'Orphelines' Pulmonaires. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum. 63, 295-304 (2011).
24. Raghu G, Collard HR, Egan JJ et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. J. Respir. Crit. Care Med. 183, 788-824 (2011).
25. Nanki N, Fujita J, Yamaji Y et al. Nonspecific interstitial pneumonia/fibrosis completely recovered by adding cyclophosphamide to corticosteroids. Intern. Med. 41, 867-870 (2002).
26. Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: A case report. J. Korean Med. Sci. 17, 270-273 (2002).
27. Cohen JM, Miller A, Spiera H. Interstitial pneumonitis complicating rheumatoid arthritis. Sustained remission with azathioprine therapy. Chest 72, 521-524 (1977).
28. DeMarco PJ, Weisman MH, Seibold JR et al. Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum. 46, 2983-2989 (2002).
29. Tashkin DP, Elashoff R, Clements PJ et al.; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354, 2655-2666 (2006).
30. Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54, 3962-3970 (2006).
31. Zamora AC, Wolters PJ, Collard HR et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir. Med. 102, 150-155 (2008).
32. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133, 455-460 (2008).
33. Nadashkevich O, Davis P, Fritzler M et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin. Rheumatol. 25, 205-212 (2006).
34. Bérezné A, Ranque B, Valeyre D et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: A retrospective multicenter open-label study. J. Rheumatol. 35, 1064-1072 (2008).
35. de Clerck LS, Dequeker J, Francx L et al. d-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study. Arthritis Rheum. 30, 643-650 (1987).
36. Steen VD, Owens GR, Redmond C et al. The effect of d-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum. 28, 882-888 (1985).
37. Clements PJ, Furst DE, Wong WK et al. High-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 42, 1194-1203 (1999).
38. Guttadauria M, Diamond H, Kaplan D. Colchicine in the treatment of scleroderma. J. Rheumatol. 4, 272-276 (1977).
39. Schachna L, Medsger TA Jr, Dauber JH et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 54, 3954-3961 (2006).
40. Goh NS, Desai SR, Veeraraghavan S et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am. J. Respir. Crit. Care Med. 177, 1248-1254 (2008).
41. Takada K, Nagasaka K, Miyasaka N. Polymyositis/DM and interstitial lung disease: A new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 38, 383-392 (2005).
42. Ochi S, Nanki T, Takada K et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/DM. Clin. Exp. Rheumatol. 23, 707-710 (2005).
43. Wilkes MR, Sereika SM, Fertig N et al. Treatment of antisynthetase- associated interstitial lung disease with tacrolimus. Arthritis Rheum. 52, 2439-2446 (2005).
44. Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/DM: population based experience in 6 patients and literature review. J. Rheumatol. 27, 2855-2859 (2000).
45. Maeda K, Kimura R, Komuta K et al. Cyclosporine treatment for polymyositis/DM: Is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand. J. Rheumatol. 26, 24-29 (1997).
46. Suzuki Y, Hayakawa H, Miwa S et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/DM. Lung 187, 201-206 (2009).
47. Deheinzelin D, Capelozzi VL, Kairalla RA et al. Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment. Am. J. Respir. Crit. Care Med. 154(3 Pt 1), 794-799 (1996).
48. Swigris JJ, Olson AL, Fischer A et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130, 30-36 (2006).
49. Weinrib L, Sharma OP, Quismorio FP Jr. A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin. Arthritis Rheum. 20, 48-56 (1990).
50. Nakano M, Hasegawa H, Takada T et al. Pulmonary diffusion capacity in patients with systemic lupus erythematosus. Respirology 7, 45-49 (2002).
51. Lindsay K, Melsom R, Jacob BK et al. Acute progression of interstitial lung disease: A complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford) 45, 1048-1049 (2006).
52. Ostor AJ, Crisp AJ, Somerville MF et al. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 329, 1266 (2004).
53. Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 122, 1093-1096 (2002).
54. Cornec D, Avouac J, Youinou P et al. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun. Rev. 8, 515-519 (2009).
55. Okamoto H, Kamatani N. Rituximab for rheumatoid arthritis. N. Engl. J. Med. 351, 1909 (2004).
56. Yoo WH. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol. Int. doi:10.1007/s00296-009-1347-z (2010) (Epub ahead of print).
57. Daoussis D, Liossis SN, Tsamandas AC et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin. Arthritis Rheum. 40, 127-136 (2010).
58. Daoussis D, Liossis SN, Tsamandas AC et al. Experience with rituximab in scleroderma: Results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49, 271-280 (2010).
59. Lafyatis R, Kissin E, York M et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 60, 578-583 (2009).
60. Rios Fernández R, Callejas Rubio JL, Sánchez Cano D et al. Rituximab in the treatment of DM and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin. Exp. Rheumatol. 27, 1009-1016 (2009).
61. King TE Jr, Behr J, Brown KK et al. BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 177, 75-81 (2008).
62. Silver RM. Endothelin and scleroderma lung disease. Rheumatology (Oxford) 47(Suppl 5), v25-v26 (2008).
63. Azuma A, Nukiwa T, Tsuboi E et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 171, 1040-1047 (2005).
64. Nagai S, Hamada K, Shigematsu M et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med. 41, 1118-1123 (2002).
65. Okamoto H, Kobayashi A. Tyrosine kinases in rheumatoid arthritis. J. Inflamm. 8, 21 (2011).
66. Okamoto H, Yoshio T, Kaneko H et al. Inhibition of NF-kappaB signaling by fasudil as a potential therapeutic strategy for rheumatoid arthritis. Arthritis Rheum. 62, 82-92 (2010).
67. Rosenbloom J, Jiménez SA. Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: The coming of a promising new era in the treatment of tissue fibrosis. Arthritis Rheum. 58, 2219-2224 (2008).
68. Khanna D, Saggar R, Mayes MD et al. A one-year, Phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 63, 3540-3546 (2011).
69. Richeldi L, Costabel U, Selman M et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 365, 1079-1087 (2011).
70. Okamoto H, Hoshi D, Kiire A et al. Molecular targets of rheumatoid arthritis. Inflamm. Allergy Drug Targets 7, 53-66 (2008).
71. Okamoto H. Molecular aspects of rheumatoid arthritis: Chemokines, environmental factors and transcription factors. FEBS J. 275, 4447 (2008)